


Biochemistry J, 2012, 446(2):235-41; Bao X. *et al.*, J.Histochem Cytochem, 2013, 61(3):206-17; Nicholas C. *et al.*, PLoS ONE, 2013, 8(9):e74710; Stopa N. *et al.*, Cellular and Molecular Life Sciences, 2015, 72(11):2014-59).


[0008] PRMT5 is therefore considered to be a clinically relevant target and potential. PRMT5 inhibitors are under development as specified in the applications, such as, WO 2017153518A1, WO 2017153186A1, WO2016034671A1, WO216034673A1, WO2016034675A1, WO2016022605A1, and WO2015200677A2. However, there is still a need for novel, potent, PRMT5 inhibitors as anti-cancer therapies.


SUMMARY

[0009] In one aspect, the present disclosure refers to a compound of Formula I, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, wherein




Formula I



wherein A is selected from  or ; ---- represents optional single or double bond; n is 0 or 1; m is 0 - 2; p is 1 or 2; o is 1 - 3; R¹, R², R³, R⁴, R⁵, and R⁶ are independently selected from hydrogen, halogen, hydroxyl or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more groups selected from hydroxyl, or halogen; R⁷, and R¹² are independently selected from hydrogen or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with C₅₋₆ aryl, and wherein C₅₋₆ aryl is optionally substituted with one or more groups selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl, or cyano; R^{11a}, R^{11b}, R^{11c}, R^{11d}, R^{13a}, R^{13b}, R^{13c}, and R^{13d} are independently selected from hydrogen, halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl or C₁₋₆ alkoxy; X, Y, and Z are independently selected from CR¹⁰, NR¹⁰, O, or S; W, and B are independently selected from N or C; R⁸ is absent or is selected from hydrogen, halogen,



C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heteroaryl or C₃₋₁₅ heterocyclyl; and R¹⁰ is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₁₋₆ alkylamino, COOR_a, C(O)R_b, C(S)R_a, C(O)NR_aR_b, C(S)NR_aR_b, NR^aC(O)NR_bR_c, N(R_a)SOR_b, N(R_a)SO₂R_b, NR_aC(O)OR_b, NR_aR_b, NR_aC(S)NR_bR_c, NR_aC(O)R_b, NR_aC(S)R_b, SF₅, SONR_aR_b, SO₂NR_aR_b, OC(O)NR_aR_b, OR_aC(O)OR_b, OC(O)NR_aR_b, OC(O)R_a, OR_a, R_aNR_bR_c, R_aOR_b, SR_a, SOR_a, SO₂R_a, or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, oxo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, C(O)R_b, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl, or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.



[00010] In another aspect, the present disclosure refers to a compound of Formula Ia, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, wherein



together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

[00011] In yet another aspect, the present disclosure refers to a compound of Formula Ib, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, wherein




wherein A is selected from  or  ; n is 0 or 1; m is 0 - 2; p is 1; o is 1 - 3; R¹, R², R³, and R⁴ are independently selected from hydrogen, halogen, hydroxyl, or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with hydroxyl, or halogen; R⁵, and R⁶ are independently selected from hydrogen, C₁₋₆ alkyl, or halogen, wherein C₁₋₆ alkyl is optionally substituted with hydroxyl, or halogen; R⁷, and R¹² are independently selected from hydrogen or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with C₅₋₆ aryl, and wherein C₅₋₆ aryl is optionally substituted with one or more groups selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl, or cyano; R^{11a}, R^{11b}, R^{11c}, R^{11d}, R^{13a}, R^{13b}, R^{13c}, and R^{13d} are independently selected from hydrogen, halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or C₁₋₆ alkoxy; X, Y, and Z are independently selected from CR¹⁰, NR¹⁰, O, or S; W is selected from N or C; R⁸ is absent or is selected from hydrogen, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heteroaryl or C₃₋₁₅ heterocyclyl; and R¹⁰ is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₁₋₆ alkylamino, COOR_a, C(O)R_b, C(S)R_a, C(O)NR_aR_b, C(S)NR_aR_b, NR^aC(O)NR_bR_c, N(R_a)SOR_b, N(R_a)SO₂R_b, NR_aC(O)OR_b, NR_aR_b, NR_aC(S)NR_bR_c, NR_aC(O)R_b,

NR_aC(S)R_b, SONR_aR_b, SO₂NR_aR_b, OC(O)NR_aR_b, OR_aC(O)OR_b, OC(O)NR_aR_b, OC(O)R_a, OR_a, R_aNR_bR_c, R_aOR_b, SR_a, SOR_a, SO₂R_a, or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, oxo, C₃₋₆ cycloalkyl, C(O)R_b, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

[00012] The present disclosure further describes the process of preparation of compounds of Formula I, Formula Ia, or Formula Ib, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof.


[00012a] In yet another aspect, the present disclosure refers to a process of preparation of compounds of Formula I as disclosed herein, or its analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, the process comprising reacting Formula II, and Formula III



in presence of a coupling reagent and a solvent to obtain the compounds of Formula I, wherein X, Y, and Z of Formula III are independently selected from CR¹⁰, NR¹⁰, O or S; W and B are independently selected from N or C, p is 1 or 2; o is 1 – 3; R⁸ is absent or is selected from hydrogen, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heteroaryl or C₃₋₁₅ heterocyclyl, and R¹⁰ is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl,


C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₁₋₆ alkylamino, COOR_a, C(O)R_b, C(S)R_a, C(O)NR_aR_b, C(S)NR_aR_b, NR^aC(O)NR_bR_c, N(R_a)SOR_b, N(R_a)SO₂R_b, NR_aC(O)OR_b, NR_aR_b, NR_aC(S)NR_bR_c, NR_aC(O)R_b, NR_aC(S)R_b, SONR_aR_b, SO₂NR_aR_b, OC(O)NR_aR_b, OR_aC(O)OR_b, OC(O)NR_aR_b, OC(O)R_a, OR_a, R_aNR_bR_c, R_aOR_b, SR_a, SOR_a, SO₂R_a or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, and C₃₋₁₅ heteroaryl are optionally substituted with C₁₋₆ alkyl; n is 0-1;

A of Formula II is selected from



n is 0 - 1; m is 0 - 2; o is 1 - 3; R¹, R², R³, and R⁴ are independently selected from hydrogen, halogen, hydroxyl or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with hydroxyl, halogen, and combinations thereof; R⁵, and R⁶ are independently selected from hydrogen, C₁₋₆ alkyl or halogen, wherein C₁₋₆ alkyl is optionally substituted with hydroxyl, halogen, and combinations thereof; R⁷, and R¹² are independently selected from hydrogen or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with C₅₋₆ aryl, and wherein C₅₋₆ aryl is optionally substituted with one or more groups selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl or cyano; R^{11a}, R^{11b}, R^{11c}, R^{11d}, R^{13a}, R^{13b}, R^{13c}, and R^{13d} are independently selected from hydrogen, halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl or C₁₋₆ alkoxy

A of Formula I is selected from



---- represents optional single or double bond; n is 0 or 1; m is 0 - 2; p is 1 or 2; o is 1 - 3; R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are independently selected from hydrogen, halogen, hydroxyl or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more groups selected from hydroxyl or halogen; R^7 , and R^{12} are independently selected from hydrogen or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with C_{5-6} aryl, and wherein C_{5-6} aryl is optionally substituted with one or more groups selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, hydroxyl, or cyano; R^{11a} , R^{11b} , R^{11c} , R^{11d} , R^{13a} , R^{13b} , R^{13c} , and R^{13d} are independently selected from hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} alkoxy; X, Y, and Z are independently selected from CR^{10} , NR^{10} , O or S; W, and B are independently selected from N or C; R^8 is absent or is selected from hydrogen, halogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heteroaryl or C_{3-15} heterocyclyl; and R^{10} is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{1-6} alkylamino, $COOR_a$, $C(O)R_b$, $C(S)R_a$, $C(O)NR_aR_b$, $C(S)NR_aR_b$, $NR^aC(O)NR_bR_c$, $N(R_a)SOR_b$, $N(R_a)SO_2R_b$, $NR_aC(O)OR_b$, NR_aR_b , $NR_aC(S)NR_bR_c$, $NR_aC(O)R_b$, $NR_aC(S)R_b$, $SONR_aR_b$, $SO_2NR_aR_b$, $OC(O)NR_aR_b$, $OR_aC(O)OR_b$, $OC(O)NR_aR_b$, $OC(O)R_a$, OR_a , $R_aNR_bR_c$, R_aOR_b , SR_a , SOR_a , SO_2R_a or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, $C(O)R_b$, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with $C(O)R_b$, and wherein R_a , R_b , and R_c are independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heterocyclyl or C_{3-15} heteroaryl, wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and C_{3-15} heteroaryl are optionally substituted with one or more substituents selected from halogen,

cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

[00013] In yet another aspect, the present disclosure refers to a pharmaceutical composition comprising a compound of Formula I, Formula Ia, or Formula Ib or a pharmaceutically acceptable salt thereof as disclosed herein together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.

[00014] The present disclosure further relates to a method for the treatment and/or prevention of various diseases, including cancer and infectious diseases, comprising administering to a subject suffering from the proliferative disorder or cancer a therapeutically effective amount of the compound of Formula I, Formula Ia, or Formula Ib or the pharmaceutical composition, with other clinically relevant cytotoxic agents or non-cytotoxic agents to a subject in need thereof. In yet another aspect, the present disclosure refers to use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein, in the manufacture of a medicament for treatment and/or prevention of various diseases, including cancer and infectious disease, wherein said medicament is to be administered in combination with other clinically relevant cytotoxic agents or non-cytotoxic agents, wherein the compound or the pharmaceutical composition is to be administered to a subject suffering from the proliferative disorder or cancer.

[00014a] In yet another aspect, the present disclosure refers to use of the compounds as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for the treatment and/or prevention of various diseases including proliferative disorder or cancer; or treatment of cancer, wherein said medicament is to be administered together in combination with other clinically relevant cytotoxic agents or non-cytotoxic agents.

[00014b] In yet another aspect, the present disclosure refers to use of the compounds as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treatment of cancer, wherein said medicament is to be administered in combination with other clinically relevant cytotoxic agents or non-cytotoxic agents.

[00014c] In yet another aspect, the present disclosure refers to use of the compounds as disclosed herein or the pharmaceutical composition as disclosed herein in the

manufacture of a medicament for treatment of cancer, wherein said medicament is to be administered in combination with other clinically relevant immune modulator agents.


[00014d] In yet another aspect, the present disclosure refers to use of the compounds as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treatment of a condition mediated by PRMT5; treatment and/or prevention of a proliferative disorder or cancer; or treatment of cancer, wherein said medicament is to be administered together in combination with other clinically relevant cytotoxic agents or non-cytotoxic agents.

[00014e] In yet another aspect, the present disclosure refers to use of the compound as disclosed herein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for the treatment and/or prevention of a condition mediated by PRMT5 or a proliferative disorder or cancer.

[00015] These and other features, aspects, and advantages of the present subject matter will become better understood with reference to the following description. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the disclosure, nor is it intended to be used to limit the scope of the subject matter.


I/We claim:

1. A compound of Formula I



Formula I

their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof,
wherein A is selected from



---- represents optional single or double bond;

n is 0 or 1;

m is 0 - 2;

p is 1 or 2;

o is 1 – 3;

R¹, R², R³, R⁴, R⁵, and R⁶ are independently selected from hydrogen, halogen, hydroxyl, or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more groups selected from hydroxyl, or halogen;

R⁷, and R¹² are independently selected from hydrogen or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with C₅₋₆ aryl, and wherein C₅₋₆ aryl is optionally substituted with one or more groups selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl, or cyano;

R^{11a}, R^{11b}, R^{11c}, R^{11d}, R^{13a}, R^{13b}, R^{13c}, and R^{13d} are independently selected from hydrogen, halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or C₁₋₆ alkoxy;

X, Y, and Z are independently selected from CR¹⁰, NR¹⁰, O, or S;


W, and B are independently selected from N or C;

R⁸ is absent or is selected from hydrogen, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heteroaryl, or C₃₋₁₅ heterocyclyl; and

R¹⁰ is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₁₋₆ alkylamino, COOR_a, C(O)R_b, C(S)R_a, C(O)NR_aR_b, C(S)NR_aR_b, NR^aC(O)NR_bR_c, N(R_a)SOR_b, N(R_a)SO₂R_b, NR_aC(O)OR_b, NR_aR_b, NR_aC(S)NR_bR_c, NR_aC(O)R_b, NR_aC(S)R_b, SF₅, SONR_aR_b, SO₂NR_aR_b, OC(O)NR_aR_b, OR_aC(O)OR_b, OC(O)NR_aR_b, OC(O)R_a, OR_a, R_aNR_bR_c, R_aOR_b, SR_a, SOR_a, SO₂R_a, or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, oxo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, C(O)R_b, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl, or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

2. The compound of Formula I as claimed in claim 1, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, wherein

A is selected from



or ;

---- represents optional single or double bond;

n is 0 or 1;

m is 0 - 2;

p is 1;

o is 1 or 2;

R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are independently selected from hydrogen, halogen, hydroxyl, or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more groups selected from hydroxyl and halogen;

R^7 , and R^{12} are independently selected from hydrogen, or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with C_{5-6} aryl, and wherein C_{5-6} aryl is optionally substituted with one or more groups selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, hydroxyl, or cyano;

R^{11a} , R^{11b} , R^{11c} , R^{11d} , R^{13a} , R^{13b} , R^{13c} , and R^{13d} are independently selected from hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, or C_{1-6} alkoxy;

X, Y, and Z are independently selected from CR^{10} , NR^{10} , O, or S;


W, and B are independently selected from N or C;

R^8 is absent or is selected from hydrogen, halogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heteroaryl, or C_{3-15} heterocyclyl; and

R^{10} is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{1-6} alkylamino, $COOR_a$, $C(O)R_b$, $C(S)R_a$, $C(O)NR_aR_b$, $C(S)NR_aR_b$, $NR^aC(O)NR_bR_c$, $N(R_a)SOR_b$, $N(R_a)SO_2R_b$, $NR_aC(O)OR_b$, NR_aR_b , $NR_aC(S)NR_bR_c$, $NR_aC(O)R_b$, $NR_aC(S)R_b$, SF_5 , $SONR_aR_b$, $SO_2NR_aR_b$, $OC(O)NR_aR_b$, $OR_aC(O)OR_b$, $OC(O)NR_aR_b$, $OC(O)R_a$, OR_a , $R_aNR_bR_c$, R_aOR_b , SR_a , SOR_a , SO_2R_a , or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, oxo, C_{1-6}


alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, C(O)R_b, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₆ cycloalkyl, C₃₋₁₅ heterocyclyl, or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

3. A compound of Formula Ia



their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof,

wherein A is selected from



or ;

n is 0 or 1;

m is 0 - 2;

o is 1 – 3;

R¹, R², R³, R⁴, R⁵, and R⁶ are independently selected from hydrogen, halogen, hydroxyl, or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more groups selected from hydroxyl, or halogen;

R⁷ and R¹² are independently selected from hydrogen, and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with C₅₋₆ aryl, and wherein C₅₋₆ aryl is optionally substituted with one or more groups selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl, or cyano;

R^{11a}, R^{11b}, R^{11c}, R^{11d}, R^{13a}, R^{13b}, R^{13c}, and R^{13d} are independently selected from hydrogen, halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or C₁₋₆ alkoxy;

Y¹, Y², and Y³ are independently selected from N or CH;


W is selected from N or C;

R⁸ is absent or is selected from hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heteroaryl, or C₃₋₁₅ heterocyclyl; and

R¹⁰ is selected from hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ aryl, 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, C₁₋₆ alkylamino, COOR_a, C(O)R_b, C(S)R_a, C(O)NR_aR_b, C(S)NR_aR_b, NR^aC(O)NR_bR_c, N(R_a)SOR_b, N(R_a)SO₂R_b, NR_aC(O)OR_b, NR_aR_b, NR_aC(S)NR_bR_c, NR_aC(O)R_b, NR_aC(S)R_b, SF₅, SONR_aR_b, SO₂NR_aR_b, OC(O)NR_aR_b, OR_aC(O)OR_b, OC(O)NR_aR_b, OC(O)R_a, OR_a, R_aNR_bR_c, R_aOR_b, SR_a, SOR_a, or SO₂R_a, wherein C₅₋₆ aryl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, cyano, oxo, C₃₋₆ cycloalkyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, C(O)R_b, 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl, and C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

4. The compound of Formula Ia as claimed in claim 3, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof, wherein

A is selected from



or ;

n is 0 or 1;

m is 0 - 2;

o is 1 - 3;

R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, and C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more groups selected from hydroxyl, or halogen;

R^7 and R^{12} are independently selected from hydrogen, and C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with C_{5-6} aryl, wherein C_{5-6} aryl is optionally substituted with one or more groups selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy, halogen, hydroxyl, or cyano;

R^{11a} , R^{11b} , R^{11c} , R^{11d} , R^{13a} , R^{13b} , R^{13c} , and R^{13d} are independently selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, or C_{1-6} alkoxy;

Y^1 , Y^2 , and Y^3 are independently selected from N or CH;


W is selected from N or C;

R^8 is absent or is selected from hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heteroaryl, or C_{3-15} heterocyclyl; and

R^{10} is selected from hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} aryl, 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, C_{1-6} alkylamino, $COOR_a$, $C(O)R_b$, $C(S)R_a$, $C(O)NR_aR_b$, $C(S)NR_aR_b$, $NR^aC(O)NR_bR_c$, $N(R_a)SOR_b$, $N(R_a)SO_2R_b$, $NR_aC(O)OR_b$, NR_aR_b , $NR_aC(S)NR_bR_c$, $NR_aC(O)R_b$, $NR_aC(S)R_b$, SF_5 , $SONR_aR_b$, $SO_2NR_aR_b$, $OC(O)NR_aR_b$, $OR_aC(O)OR_b$, $OC(O)NR_aR_b$, $OC(O)R_a$, OR_a , $R_aNR_bR_c$,

R_aOR_b , SR_a , SOR_a and SO_2R_a , wherein C_{5-6} aryl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with $C(O)R_b$, and wherein R_a , R_b , and R_c are independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heterocyclyl, and C_{3-15} heteroaryl, wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and C_{3-15} heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C_{1-6} alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

5. The compound of Formula Ia as claimed in claim 3, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof, wherein A is selected from



OR ;

n is 0 or 1;

m is 0 - 2;

o is 1 – 3;

R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more groups selected from hydroxyl, or halogen;

R^7 and R^{12} are independently selected from hydrogen, or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with C_6 aryl, and wherein C_6 aryl is optionally substituted with one or more groups selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, halogen, hydroxyl, or cyano;


R^{11a} , R^{11b} , R^{11c} , R^{11d} , R^{13a} , R^{13b} , R^{13c} , and R^{13d} are independently selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, or C_{1-6} alkoxy; Y^1 , Y^2 , and Y^3 are independently selected from N or CH;

W is selected from N or C;

R^8 is absent or is selected from hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heteroaryl, and C_{3-15} heterocyclyl; and

R^{10} is selected from hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} aryl, 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, C_{1-6} alkylamino, $COOR_a$, $C(O)R_b$, $C(S)R_a$, $C(O)NR_aR_b$, $C(S)NR_aR_b$, $NR^aC(O)NR_bR_c$, $N(R_a)SOR_b$, $N(R_a)SO_2R_b$, $NR_aC(O)OR_b$, NR_aR_b , $NR_aC(S)NR_bR_c$, $NR_aC(O)R_b$, $NR_aC(S)R_b$, SF_5 , $SONR_aR_b$, $SO_2NR_aR_b$, $OC(O)NR_aR_b$, $OR_aC(O)OR_b$, $OC(O)NR_aR_b$, $OC(O)R_a$, OR_a , $R_aNR_bR_c$, R_aOR_b , SR_a , SOR_a and SO_2R_a , wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, $C(O)R_b$, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, and wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with $C(O)R_b$, wherein R_a , R_b , and R_c are independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heterocyclyl, and C_{3-15} heteroaryl, wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and C_{3-15} heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C_{1-6} alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

6. The compound of Formula Ia as claimed in claim 3, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof, wherein A is selected from



or ;

n is 0 or 1;

m is 0 or 1;

o is 1 – 3;

R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, and C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more groups selected from hydroxyl, fluoro, chloro, or bromo;

R^7 and R^{12} are independently selected from hydrogen, and C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with C_6 aryl, and wherein C_6 aryl is optionally substituted with one or more groups selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, halogen, hydroxyl, or cyano;

R^{11a} , R^{11b} , R^{11c} , R^{11d} , R^{13a} , R^{13b} , R^{13c} , and R^{13d} are independently selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, or C_{1-6} alkoxy;

Y^1 , Y^2 , and Y^3 are independently selected from N or CH;


W is selected from N or C;

R^8 is absent or is selected from hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkenyl, C_{1-4} alkynyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heteroaryl, and C_{3-15} heterocyclyl; and


R^{10} is selected from hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} aryl, 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, C_{1-4} alkylamino, $COOR_a$, $C(O)R_b$, $C(S)R_a$, $C(O)NR_aR_b$, $C(S)NR_aR_b$, $NR^aC(O)NR_bR_c$, $NR_aC(S)NR_bR_c$, $N(R_a)SOR_b$, $N(R_a)SO_2R_b$, $NR_aC(O)OR_b$, NR_aR_b , $NR_aC(O)R_b$, $NR_aC(S)R_b$, SF_5 , $SONR_aR_b$, $SO_2NR_aR_b$, OR_a , $OR_aC(O)OR_b$, $OC(O)NR_aR_b$, $OC(O)R_a$, $OC(O)NR_aR_b$, $R_aNR_bR_c$, R_aOR_b , SR_a , SOR_a and SO_2R_a , wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, cyano, oxo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{3-6} cycloalkyl, $C(O)R_b$, 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected

from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₆ cycloalkyl, C₃₋₁₅ heterocyclyl, and C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

7. A compound of Formula Ib



their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof,
wherein A is selected from



or ;

n is 0 or 1;

m is 0 - 2;

p is 1;

o is 1 – 3;

R¹, R², R³, and R⁴ are independently selected from hydrogen, halogen, hydroxyl, or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more groups selected from hydroxyl, or halogen;

R⁵, and R⁶ are independently selected from hydrogen, C₁₋₆ alkyl, or halogen, wherein C₁₋₆ alkyl is optionally substituted with one or more groups selected from hydroxyl, or halogen;

R⁷, and R¹² are independently selected from hydrogen, or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with C₅₋₆ aryl, and wherein C₅₋₆ aryl is optionally substituted with one or more groups selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl, or cyano;

R^{11a}, R^{11b}, R^{11c}, R^{11d}, R^{13a}, R^{13b}, R^{13c}, and R^{13d} are independently selected from hydrogen, halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or C₁₋₆ alkoxy;

X, Y, and Z are independently selected from CR¹⁰, NR¹⁰, O, or S;

W is selected from N or C;


R⁸ is absent or is selected from hydrogen, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heteroaryl or C₃₋₁₅ heterocyclyl; and

R¹⁰ is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₁₋₆ alkylamino, COOR_a, C(O)R_b, C(S)R_a, C(O)NR_aR_b, C(S)NR_aR_b, NR^aC(O)NR_bR_c, N(R_a)SOR_b, N(R_a)SO₂R_b, NR_aC(O)OR_b, NR_aR_b, NR_aC(S)NR_bR_c, NR_aC(O)R_b, NR_aC(S)R_b, SONR_aR_b, SO₂NR_aR_b, OC(O)NR_aR_b, OR_aC(O)OR_b, OC(O)NR_aR_b, OC(O)R_a, OR_a, R_aNR_bR_c, R_aOR_b, SR_a, SOR_a, SO₂R_a, or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, oxo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, C(O)R_b, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

8. The compound of Formula Ib as claimed in claim 7, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates,

pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, wherein

A is selected from



or ;

n is 0 or 1;

m is 0 or 1;

p is 1;

o is 1 – 3;

R^1 , R^2 , R^3 , and R^4 are independently selected from hydrogen, halogen, hydroxyl or C_{1-5} alkyl, wherein C_{1-5} alkyl is optionally substituted with one or more groups selected from hydroxyl, or halogen;

R^5 , and R^6 are independently selected from hydrogen, C_{1-5} alkyl or halogen, wherein C_{1-5} alkyl is optionally substituted with hydroxyl and halogen;

R^7 , and R^{12} are independently selected from hydrogen or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with C_{5-6} aryl, and wherein C_{5-6} aryl is optionally substituted with one or more groups selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, hydroxyl or cyano;

R^{11a} , R^{11b} , R^{11c} , R^{11d} , R^{13a} , R^{13b} , R^{13c} , and R^{13d} are independently selected from hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} alkoxy;

X, Y, and Z are independently selected from C, R^{10} , NR^{10} , O or S;


W is selected from N or C;

R^8 is absent or is selected from hydrogen, halogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heteroaryl or C_{3-15} heterocyclyl; and

R^{10} is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{1-6} alkylamino, $COOR_a$, $C(O)R_b$, $C(S)R_a$, $C(O)NR_aR_b$, $C(S)NR_aR_b$, $NR_aC(O)NR_bR_c$, $N(R_a)SOR_b$, $N(R_a)SO_2R_b$, $NR_aC(O)OR_b$, NR_aR_b , $NR_aC(S)NR_bR_c$, $NR_aC(O)R_b$, $NR_aC(S)R_b$, $SONR_aR_b$, $SO_2NR_aR_b$, $OC(O)NR_aR_b$, $OR_aC(O)OR_b$, $OC(O)NR_aR_b$, $OC(O)R_a$, OR_a , $R_aNR_bR_c$, R_aOR_b , SR_a , SOR_a , SO_2R_a or 3-

15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, oxo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, C(O)R_b, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

9. The compound of Formula Ib as claimed in claim 7, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, wherein A is selected from



or ;

n is 0 or 1;

m is 0 or 1;

p is 1;


o is 1 – 3;

R¹, R², R³, and R⁴ are independently selected from hydrogen, halogen, hydroxyl, or C₁₋₄ alkyl, wherein C₁₋₄ alkyl is optionally substituted with one or more groups selected from hydroxyl, chloro, bromo, fluoro, or iodo;

R⁵, and R⁶ are independently selected from hydrogen, C₁₋₄ alkyl, or halogen, wherein C₁₋₄ alkyl is optionally substituted with one or more groups selected from hydroxyl, chloro, bromo, fluoro, or iodo,;

R^7 , and R^{12} are independently selected from hydrogen or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with C_6 aryl, and wherein C_6 aryl is optionally substituted with one or more groups selected from C_{1-4} alkyl, C_{1-4} alkoxy, halogen, hydroxyl, or cyano; R^{11a} , R^{11b} , R^{11c} , R^{11d} , R^{13a} , R^{13b} , R^{13c} , and R^{13d} are independently selected from hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, or C_{1-6} alkoxy; X, Y, and Z are independently selected from CR^{10} , NR^{10} , O or S; W is selected from N or C; R^8 is absent or is selected from hydrogen, halogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heteroaryl or C_{3-15} heterocyclyl; and R^{10} is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{1-6} alkylamino, $COOR_a$, $C(O)R_b$, $C(S)R_a$, $C(O)NR_aR_b$, $C(S)NR_aR_b$, $NR^dC(O)NR_bR_c$, $N(R_a)SOR_b$, $N(R_a)SO_2R_b$, $NR_aC(O)OR_b$, NR_aR_b , $NR_aC(S)NR_bR_c$, $NR_aC(O)R_b$, $NR_aC(S)R_b$, $SONR_aR_b$, $SO_2NR_aR_b$, $OC(O)NR_aR_b$, $OR_aC(O)OR_b$, $OC(O)NR_aR_b$, $OC(O)R_a$, OR_a , $R_aNR_bR_c$, R_aOR_b , SR_a , SOR_a , SO_2R_a or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, oxo, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, $C(O)R_b$, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring is optionally substituted with $C(O)R_b$, and wherein R_a , R_b , and R_c are independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heterocyclyl or C_{3-15} heteroaryl, wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and C_{3-15} heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C_{1-6} alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S, or O.

10. The compound of Formula Ib as claimed in claim 7, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, wherein A is selected from



or ;

n is 0 or 1;

m is 0 or 1;

p is 1;

o is 1 – 3;

R^1 , R^2 , R^3 , and R^4 are independently selected from hydrogen, halogen, hydroxyl, or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more groups selected from hydroxyl, fluoro, or chloro;

R^5 , and R^6 are independently selected from hydrogen, C_{1-4} alkyl or halogen, wherein C_{1-4} alkyl is optionally substituted with one or more groups selected from hydroxyl, chloro, bromo, fluoro, or iodo;

R^7 , and R^{12} are independently selected from hydrogen or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with C_6 aryl, and wherein C_6 aryl is optionally substituted with one or more groups selected from C_{1-4} alkyl, C_{1-4} alkoxy, halogen, hydroxyl or cyano;

R^{11a} , R^{11b} , R^{11c} , R^{11d} , R^{13a} , R^{13b} , R^{13c} , and R^{13d} are independently selected from hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} alkoxy;

X, Y, and Z are independently selected from CR^{10} , NR^{10} , O or S;

W is selected from N or C;

R^8 is absent or is selected from hydrogen, halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{3-15} heteroaryl or C_{3-15} heterocyclyl; and

R^{10} is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} aryl, C_{1-4} alkylamino, $COOR_a$, $C(O)R_b$, $C(S)R_a$, $C(O)NR_aR_b$, $C(S)NR_aR_b$, $NR^aC(O)NR_bR_c$, $NR_aC(S)NR_bR_c$, $N(R_a)SOR_b$, $N(R_a)SO_2R_b$, $NR_aC(O)OR_b$, NR_aR_b , $NR_aC(O)R_b$, $NR_aC(S)R_b$, $SONR_aR_b$, $SO_2NR_aR_b$, OR_a , $OR_aC(O)OR_b$, $OC(O)NR_aR_b$, $OC(O)R_a$, $OC(O)NR_aR_b$, $R_aNR_bR_c$, R_aOR_b , SR_a , SOR_a , SO_2R_a or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C_{5-6} aryl, C_{3-6} cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with

one or more groups selected from halogen, hydroxyl, oxo, cyano, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₃₋₆ cycloalkyl, C(O)R_b, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S, or O.

11. The compound of Formula I, Formula Ia, or Formula Ib as claimed in any one of the claims 1-10, their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, which is selected from a group consisting of:

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 1),
N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-methylimidazo[1,2-a]pyridine-2-carboxamide (Example 2),
N-(2-(3,4-dihydroisoquinolin-2(1H)-yl)-1-hydroxyethyl)-7-(4-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 3),
(S)-*N*-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-ethyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 4),
(S)-*N*-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(5-propyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 5),
(S)-*N*-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 6),
(S)-*N*-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 7),
(S)-*N*-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 8),
N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-methoxyimidazo[1,2-a]pyridine-2-carboxamide (Example 9),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-phenylimidazo[1,2-a]pyridine-2-carboxamide (Example 10),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(4-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 11),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-isopropylimidazo[1,2-a]pyridine-2-carboxamide (Example 12),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 13),

(S)-6-(4-cyanophenyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 14),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(3,5-dimethylisoxazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 15),

(S)-6-(3,5-difluorophenyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 16),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(4-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 17),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-isobutyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 18),

(S)-6-(3,6-dihydro-2H-pyran-4-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 19),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-((R)-tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 20),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 21),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 22),

(S)-6-(1-(1-acetylazetidin-3-yl)-1H-pyrazol-4-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 23),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(5-isopropyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 24),

(S)-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 25),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(tetrahydro-2H-pyran-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example-26),

(S)-6-(1-acetylpiperidin-4-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 27),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(2-methylpyrimidin-5-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 28),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(6-methylpyridin-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 29),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(6-methylpyridazin-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 30),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(2-methylthiazol-5-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 31),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(4,5-dimethylthiazol-2-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 32),

(S)-6-(5-chloropyridin-2-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 33),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 34),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 35),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-1,2,3-triazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 36),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-isopropyl-1H-1,2,3-triazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 37),

(S)-N2-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N6-methylimidazo[1,2-a]pyridine-2,6-dicarboxamide(Example 38),

(S)-6-acetamido-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 39),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-sulfamoylimidazo[1,2-a]pyridine-2-carboxamide (Example 40),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(methylsulfonamido)imidazo[1,2-a]pyridine-2-carboxamide (Example 41),

((S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-a]pyrimidine-2-carboxamide (Example 42),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrimidine-2-carboxamide (Example 43),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyrimidine-2-carboxamide (Example 44),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 45),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazine-2-carboxamide (Example 46),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 47),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-b]pyridazine-2-carboxamide (Example 48),

(S)-6-(1-acetylpiperidin-4-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-b]pyridazine-2-carboxamide (Example 49),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-b]pyridazine-2-carboxamide (Example 50),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 51),

(S)-6-(1-acetylpiperidin-4-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 52),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 53),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-3-methyl-6-(trifluoromethyl)imidazo[1,2-b]pyridazine-2-carboxamide (Example 54),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-3,6-dimethylimidazo[1,2-a]pyrazine-2-carboxamide (Example 55),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-methylimidazo[1,2-b]pyridazine-2-carboxamide (Example 56),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 57),

(S)-6-(3,3-difluoroazetidin-1-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 58),

(S)-6-(3,3-difluoroazetidin-1-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 59),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (Example 60),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(3-hydroxyoxetan-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 61),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (Example 62),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (Example 63),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-3-methyl-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 64),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-3-methyl-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 65),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-3-methyl-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 66)

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5-methylpyrazolo[1,5-a]pyrimidine-2-carboxamide (Example 67),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-3-fluoro-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (Example 68),

(S)-6-(azetidin-1-yl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 69),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 70),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 71),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-morpholinoimidazo[1,2-a]pyridine-2-carboxamide (Example 72),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 73),

(S)-6-(4-cyanophenyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 74),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 75),

N-((2S,3S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,3-dihydroxybutyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 76),

N-((2R,3R)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,3-dihydroxybutyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 77),
 N-((2S,3S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,3-dihydroxybutyl)-6-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 78),
 N-((2S,3S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,3-dihydroxybutyl)-6-(1-((R)-tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 79),
 N-((2S,3S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,3-dihydroxybutyl)-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 80),
 N-((2S,3S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,3-dihydroxybutyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 81),
 (S)-N-(3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 82),
 (S)-N-(3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-b]pyridazine-2-carboxamide (Example 83),
 (S)-N-(3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 84),
 (S)-N-(3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 85),
 (S)-6-(difluoromethyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 86),
 6-(difluoromethyl)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 87),
 (R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methyl-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 88),
 (R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methyl-6-(trifluoromethyl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 89),
 (R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methyl-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (Example 90),
 (R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methyl-6-(trifluoromethyl)imidazo[1,2-b]pyridazine-2-carboxamide (Example 91),
 (R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methyl-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 92),

(R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methyl-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 93),

(R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methyl-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-a]pyrazine-2-carboxamide (Example 94),

(R)-6-(4-cyanophenyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methylimidazo[1,2-a]pyrazine-2-carboxamide (Example 95),

N-(3-((2,3-dihydro-1H-inden-2-yl)amino)-2-hydroxypropyl)-6-trifluoromethylimidazo[1,2-a]pyridine-2-carboxamide (Example 96),

N-(3-((2,3-dihydro-1H-inden-2-yl)amino)-2-hydroxypropyl)-6-(tetrahydro-2H-pyran-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 97),

6-(1-acetylpiperidin-4-yl)-N-(3-((2,3-dihydro-1H-inden-2-yl)amino)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 98),

N-(3-((2,3-dihydro-1H-inden-2-yl)amino)-2-hydroxypropyl)-6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-a]pyridine-2-carboxamide (Example 99),

N-(4-(3,4-dihydroisoquinolin-2(1H)-yl)-1-hydroxybutan-2-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 100),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 101),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 102),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 103),

6-cyclopropyl-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 104),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-7-propyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 105),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-propyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 106),

(R)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-methoxy-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 107a) and (S)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-methoxy-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 107b) (Examples 107a and 107b),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-isopropyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 108),

N-(2-(3,4-dihydroisoquinolin-2(1H)-yl)-1-hydroxyethyl)-7-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 109),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 110),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 111),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-phenyl-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine-2-carboxamide (Example 112),

N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-7-isopropyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamide (Example 113),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 114),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 115),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(4-fluorophenyl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine-2-carboxamide (Example 116),

N-((2S,3S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,3-dihydroxybutyl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 117),

6-(1-acetylpiperidin-4-yl)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide- Isomer-1 (Example 118A),

(S)-6-(1-acetylpiperidin-4-yl)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 118B),

N--3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-N-methyl-6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 119),

R)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 120A),

(S)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(1-methyl-1H-pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 120B),

(S)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 121A),

(R)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 121B),

(R)-6-bromo-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 122),

(S)-6-cyano-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 123),

(R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 124),

(R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-fluoroimidazo[1,2-a]pyridine-2-carboxamide (Example 125),

(R)-2-((3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbamoyl)imidazo[1,2-a]pyridine-6-carboxylic acid (Example 126),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(piperidine-1-carbonyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 127),

(S)-N6-(3,3-difluorocyclobutyl)-N2-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2,6-dicarboxamide (Example 128),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(piperazine-1-carbonyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 129),

(S)-N6-cyclohexyl-N2-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2,6-dicarboxamide (Example 130),

(R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(2,6-diazaspiro[3.3]heptane-2-carbonyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 131),

N-((R)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 132),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(piperidine-1-carbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 133),

N6-(3,3-difluorocyclobutyl)-N2-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2,6-dicarboxamide (Example 134),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(piperazine-1-carbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 135),

N-((R)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(2,6-diazaspiro[3.3]heptane-2-carbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 136),

N-((R)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 137),

(S)-6-benzamido-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 138),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(2-fluorobenzamido)imidazo[1,2-a]pyridine-2-carboxamide (Example 139),

(S)-6-(cyclohexanecarboxamido)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 140),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(tetrahydro-2H-pyran-4-carboxamido)imidazo[1,2-a]pyridine-2-carboxamide (Example 141),

(S)-6-(cyclopropanecarboxamido)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 142),

(S)-6-(cyclobutanecarboxamido)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 143),

(S)-6-(4-cyanobenzamido)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 144),

6-(4-cyanobenzamido)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 145),

6-benzamido-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 146),

N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(isonicotinamido)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 147),

N-(2-(((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)oxazole-4-carboxamide (Example 148),

N-((R)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(tetrahydro-2H-pyran-4-carboxamido)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 149),

6-(cyclopentanecarboxamido)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 150),

6-(cyclopropanecarboxamido)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 151),

6-(cyclohexanecarboxamido)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 152),

6-(cyclobutanecarboxamido)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 153),

(R)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(phenylsulfonamido)imidazo[1,2-a]pyridine-2-carboxamide (Example 154),

N-((R)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(phenylsulfonamido)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 155),

rac-(R)-6-(azetidine-1-carbonyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 156),

(S)-N-(2-((3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbamoyl)imidazo[1,2-a]pyridin-6-yl)isoxazole-3-carboxamide (Example 157),

6-(bicyclo[2.2.1]heptane-2-carboxamido)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 158),

(S)-N-(2-((3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbamoyl)imidazo[1,2-a]pyridin-6-yl)oxazole-2-carboxamide (Example 159),

(S)-N-(2-((3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbamoyl)imidazo[1,2-a]pyridin-6-yl)thiazole-5-carboxamide (Example 160),

N-(2-(((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbamoyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)isoxazole-3-carboxamide (Example 161),

6-(bicyclo[2.2.1]heptane-2-carboxamido)-N-((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide (Example 162),

N-(2-(((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)oxazole-2-carboxamide (Example 163),


N-(2-(((S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)thiazole-5-carboxamide (Example 164),

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-ethylimidazo[1,2-a]pyridine-2-carboxamide (Example 165),

(S)-6-(1,1-difluoroethyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 166), and

(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(pentafluoro-l6-sulfaneyl)imidazo[1,2-a]pyridine-2-carboxamide (Example 167).


12. A process of preparation of compounds of Formula I as claimed in any one of claims 1 – 11, or its analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, the process comprising reacting Formula II, and Formula III



in presence of a coupling reagent and a solvent to obtain the compounds of Formula I, wherein X, Y, and Z of Formula III are independently selected from CR¹⁰, NR¹⁰, O or S; W and B are independently selected from N or C, p is 1 or 2; o is 1 – 3; R⁸ is absent or is selected from hydrogen, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heteroaryl or C₃₋₁₅ heterocyclyl, and R¹⁰ is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₁₋₆ alkylamino, COOR_a, C(O)R_b, C(S)R_a, C(O)NR_aR_b, C(S)NR_aR_b, NR^aC(O)NR_bR_c, N(R_a)SOR_b, N(R_a)SO₂R_b, NR_aC(O)OR_b, NR_aR_b, NR_aC(S)NR_bR_c, NR_aC(O)R_b, NR_aC(S)R_b, SONR_aR_b, SO₂NR_aR_b, OC(O)NR_aR_b, OR_aC(O)OR_b, OC(O)NR_aR_b, OC(O)R_a, OR_a, R_aNR_bR_c, R_aOR_b, SR_a, SOR_a, SO₂R_a or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5


heteroatoms selected from N, S or O, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, and C₃₋₁₅ heteroaryl are optionally substituted with C₁₋₆ alkyl; n is 0-1;

A of Formula II is selected from



n is 0 - 1; m is 0 - 2; o is 1 - 3; R¹, R², R³, and R⁴ are independently selected from hydrogen, halogen, hydroxyl or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with hydroxyl, halogen, and combinations thereof; R⁵, and R⁶ are independently selected from hydrogen, C₁₋₆ alkyl or halogen, wherein C₁₋₆ alkyl is optionally substituted with hydroxyl, halogen, and combinations thereof; R⁷, and R¹² are independently selected from hydrogen or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with C₅₋₆ aryl, and wherein C₅₋₆ aryl is optionally substituted with one or more groups selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl or cyano; R^{11a}, R^{11b}, R^{11c}, R^{11d}, R^{13a}, R^{13b}, R^{13c}, and R^{13d} are independently selected from hydrogen, halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl or C₁₋₆ alkoxy

A of Formula I is selected from



---- represents optional single or double bond; n is 0 or 1; m is 0 - 2; p is 1 or 2; o is 1 - 3; R¹, R², R³, R⁴, R⁵, and R⁶ are independently selected from hydrogen, halogen,

hydroxyl or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more groups selected from hydroxyl or halogen; R⁷, and R¹² are independently selected from hydrogen or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with C₅₋₆ aryl, and wherein C₅₋₆ aryl is optionally substituted with one or more groups selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl, or cyano; R^{11a}, R^{11b}, R^{11c}, R^{11d}, R^{13a}, R^{13b}, R^{13c}, and R^{13d} are independently selected from hydrogen, halogen, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl or C₁₋₆ alkoxy; X, Y, and Z are independently selected from CR¹⁰, NR¹⁰, O or S; W, and B are independently selected from N or C; R⁸ is absent or is selected from hydrogen, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heteroaryl or C₃₋₁₅ heterocyclyl; and R¹⁰ is selected from hydrogen, halogen, hydroxyl, oxo, nitro, cyano, azido, nitroso, amino, hydrazino, formyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₁₋₆ alkylamino, COOR_a, C(O)R_b, C(S)R_a, C(O)NR_aR_b, C(S)NR_aR_b, NR^aC(O)NR_bR_c, N(R_a)SOR_b, N(R_a)SO₂R_b, NR_aC(O)OR_b, NR_aR_b, NR_aC(S)NR_bR_c, NR_aC(O)R_b, NR_aC(S)R_b, SONR_aR_b, SO₂NR_aR_b, OC(O)NR_aR_b, OR_aC(O)OR_b, OC(O)NR_aR_b, OC(O)R_a, OR_a, R_aNR_bR_c, R_aOR_b, SR_a, SOR_a, SO₂R_a or 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-5 heteroatoms selected from N, S or O, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and 3-15 membered saturated or unsaturated heterocyclyl or heteroaryl ring are optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, oxo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, C(O)R_b, or 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O, wherein 3-6 membered saturated or unsaturated heterocyclyl or heteroaryl ring with 1-3 heteroatoms selected from N, S or O is optionally substituted with C(O)R_b, and wherein R_a, R_b, and R_c are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₅₋₆ aryl, C₃₋₁₅ heterocyclyl or C₃₋₁₅ heteroaryl, wherein C₅₋₆ aryl, C₃₋₆ cycloalkyl, and C₃₋₁₅ heteroaryl are optionally substituted with one or more substituents selected from halogen, cyano, or C₁₋₆ alkyl; or R_a and R_b can be taken together to form a 5-10 membered monocyclic or bicyclic, saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

13. The process as claimed in claim 12, wherein the coupling reagent is selected from the group consisting of *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride, hydroxybenzotriazole, propane phosphonic acid anhydride, and combinations thereof.

14. The process as claimed in claim 12, wherein the solvent is a polar aprotic solvent selected from the group consisting of DMF, dioxane, acetonitrile, THF, and combinations thereof.
15. A pharmaceutical composition comprising a compound of Formula I, Formula Ia, or Formula Ib or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1-11 together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
16. The pharmaceutical composition as claimed in claim 15, wherein the composition is in the form selected from the group consisting of a tablet, capsule, powder, syrup, solution, aerosol and suspension.
17. Use of the compound according to any one of claims 1 – 11 or the pharmaceutical composition as claimed in claim 15 or 16, in the manufacture of a medicament for treatment and/or prevention of various diseases, including cancer and infectious disease, wherein said medicament is to be administered in combination with other clinically relevant cytotoxic agents or non-cytotoxic agents, wherein the compound or the pharmaceutical composition is to be administered to a subject suffering from the proliferative disorder or cancer.
18. Use of the compounds as claimed in any one of claims 1 – 11 or the pharmaceutical composition as claimed in claim 15 or 16 in the manufacture of a medicament for the treatment and/or prevention of various diseases including proliferative disorder or cancer; or treatment of cancer, wherein said medicament is to be administered together in combination with other clinically relevant cytotoxic agents or non-cytotoxic agents.
19. Use of the compounds as claimed in any one of claims 1 – 11 or the pharmaceutical composition as claimed in claim 15 in the manufacture of a medicament for treatment of cancer, wherein said medicament is to be administered in combination with other clinically relevant cytotoxic agents or non-cytotoxic agents.
20. Use of the compounds as claimed in any one of claims 1 – 11 or the pharmaceutical composition as claimed in claim 15 in the manufacture of a medicament for treatment of cancer, wherein said medicament is to be administered in combination with other clinically relevant immune modulator agents.
21. Use of the compounds as claimed in any one of claims 1 - 11 or the pharmaceutical composition as claimed in claim 15 in the manufacture of a medicament for treatment of a condition mediated by PRMT5; treatment and/or prevention of a

proliferative disorder or cancer; or treatment of cancer, wherein said medicament is to be administered together in combination with other clinically relevant cytotoxic agents or non-cytotoxic agents.

22. Use of the compound as claimed in any one of claims 1 – 11 or the pharmaceutical composition as claimed in claim 15 in the manufacture of a medicament for the treatment and/or prevention of a condition mediated by PRMT5 or a proliferative disorder or cancer.